bexarotene has been researched along with celecoxib in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Henney, JE | 1 |
| Baker, R; Bissonnette, RP; Brown, PH; Dannenberg, AJ; Howe, LR; Newman, RA; Salmon, AP; Subbaramaiah, K; Yang, P; Zhou, XK | 1 |
| Bissonette, R; Brown, PH; Hill, J; Hilsenbeck, SG; Kittrell, F; Medina, D; Zhang, Y | 1 |
| Abba, MC; Aldaz, CM; Bissonnette, RP; Brown, PH; Gaddis, S; Hill, J; Hu, Y; Kittrell, FS; Levy, CC; Medina, D | 1 |
| Gould, MN; Haag, JD; Sullivan, R; Woditschka, S | 1 |
| Chang, WC; Clapper, ML; Fischer, SM; Grubbs, CJ; Juliana, MM; Lubet, RA; McCormick, DL; Pereira, MA; Steele, VE | 1 |
1 review(s) available for bexarotene and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for bexarotene and celecoxib
| Article | Year |
|---|---|
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
From the Food and Drug Administration.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Bexarotene; Celecoxib; Cisapride; Contraindications; Cyclooxygenase Inhibitors; Drug Labeling; Gastrointestinal Agents; Humans; Lymphoma, T-Cell, Cutaneous; Pyrazoles; Receptors, Retinoic Acid; Sulfonamides; Tetrahydronaphthalenes | 2000 |
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Eicosanoids; Female; Genes, erbB-2; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Transgenic; Pyrazoles; Retinoid X Receptors; Retinoids; Substrate Specificity; Sulfonamides; Tetrahydronaphthalenes | 2008 |
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Incidence; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Suppressor Protein p53 | 2009 |
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Precancerous Conditions; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Protein, Translationally-Controlled 1; Tumor Suppressor Protein p53 | 2009 |
A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Bexarotene; Carcinoma in Situ; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Genes, erbB-2; Mammary Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Pyrazoles; Rats; Rats, Inbred WF; Retroviridae; Sulfonamides; Tamoxifen; Tetrahydronaphthalenes; Time Factors | 2009 |
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Female; Head and Neck Neoplasms; Intestinal Neoplasms; Male; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Neoplasms; Pyrazoles; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Sulfonamides; Tetrahydronaphthalenes; Urinary Bladder Neoplasms | 2012 |